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patients requiring treatment for CLI (see also Critical
Issue 2, p S34). The most commonly used generic
instrument. ithe SF-36 questionnaire, has been used by
some investigators in the evaluation of small groups
of patients to determine whether its scale appropriate-
ly reflects the benefits of successful treatment.
Functional status should be followed-up for at least 6
months postprocedure. Schneider and associates!
used the SF-20, similar to the SF-36, a derivative of the
Medical Outcomes Study, to evaluate 60 patients with
CLI. This group noted that those with CLI had signif-
icant decreases in functional health and well-being
despite successful revascularisation.
Duggan and colleagues- used the SF-36 question-
naire for the evaluation of 21 patients requiring treat-
ment for CLI. Interestingly, they noted no significant
difference in physical functioning between those
patients with patent and those with failed bypasses.
Additionally, the SF-36 did not indicate that patients
with functioning bypasses had better emotional and
general well-being scores . Chetter and associates? also
employed the SF-36 to evaluate 235 patients, 78 of
whom had CLI. They noted that the quality-of-life
scores obtained through the SF-36 deteriorated as dis-
tal perfusion worsened. Thus, although there has been
no broad standardisation of the SF-36 in patients with
CLI, it represents the most obvious option at the pres-
ent (see Recommendation 3, p S36).
Improvement in[unctional status
Improvement in functional status is often difficult to
define in patients with CLI because of the presence of
numerous and often severe comorbid conditions.
Simple assessment of walking distance, though use-
ful in some patients, does not apply to many. For
example, those patients who have had a previous
major amputation of the contralateral extremity may
have an improved ability to pivot and transfer from
bed to wheelchair after successful revascularisation
of the contralateral leg. This improvement would not
be detected by any current measures of functional
status. Therefore, specific instruments capable of
detecting improvement in functional status in this
diverse patient population must be developed.
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D4
TREATMENT OF CRITICAL LIMB ISCHAEMIA ·
D 4.1
Overall Strategy for Treatment of Critical Limb
Ischaemia
Many of the principals of basic treatment discussed
in relation to patients with intermittent claudication
also apply to patients with CLI, although the urgency
for rapid treatment of the latter group will alter the
emphasis. For instance, the management of risk fac-
tors such as hyperlipidaemia is not of any immediate
importance in patients with CLI. By contrast, other
important aspects in the immediate basic treatment
of patients with CLI, such as adequate control of
pain, do not apply to claudication.
The principal urgent components of basic treat-
ment of CLI are the control of pain and any infection
in the ischaemic leg, prevention of progression of
thrombosis if this is thought to be a precipitating fac-
tor in the ischaemia, and the optimisation of cardiac
and respiratory function. While instituting basic
treatment, the full precise morphology of the PAD
should be simultaneously established by some form
of imaging technique. This will determine further
management of the arterial lesion. In a small group of
patients, often delayed referrals, ischaemia and gross
infection in the leg pose an immediate threat to the
patient's survival. An immediate major amputation
is mandatory and can be life saving in these cases, for
instance, in a patient with gas or septic gangrene.
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In most patients, the various options for endovas-
cular techniques, arterial surgery, or thrombolysis
can be carefully weighed. The primary aim is revas-
cularisation to provide sufficient blood flow to
relieve the rest pain and heal skin lesions. Most
patients with CLI have multisegment arterial disease,
and often the elimination of the most proximal
obstruction might be sufficient to achieve these aims.
It is, however, important to resist the temptation to
only treat a relatively easy proximal lesion in the
presence of extensive distal disease where the mar-
ginal improvement in blood flow may be insufficient
to achieve healing. This applies especially where
there has been tissue loss. For instance, angioplasty
for relatively minor iliac stenosis is unlikely to
achieve healing of a foot ulcer in the presence of
extensive infrainguinal disease (see also 0 4.2.2, P
5165).
In general, if there is a balanced choice between an
endovascular and a surgical procedure for a particu-
lar lesion, then the former is preferred because it
usually avoids a general anaesthesia, poses a lesser
systemic stress, and has fewer serious complications.
However, the choice between an endovascular and a
surgical procedure depends largely on the exact
level and extent of the arterial disease; hence the
need for a collaborative discussion of each case
between endovascular and surgical specialists. For
the same reason, in this section the optimal tech-
nique for revascularisation is discussed on an
anatomic basis.
Having identified the best interventional techniques
in a particular case, the risks and chances of success
have to be weighed. There is no doubt that in some
cases in which the risks of revascularisation are high
and the chances of success low, there is a place for a
primary major amputation or noninterventional ther-
apy. Although a number of techniques are available
for assessing the risks and benefit of a particular
revascularisation procedure in a particular patient,
they are still far from perfect. This is reflected by the
number of patients who have an attempt at a series of
revascularisation procedures that fail to achieve their
purpose even in the short term and culminate in a
major amputation.
There may be additional considerations in deciding
whether to advise a patient to have a primary ampu-
tation. Not infrequently, patients with CLI will have
other serious conditions limiting mobility, for
instance, a neurological deficit from previous stroke.
In fitter patients, it is necessary to estimate the chances
of a patient fully mobilising on an artificial limb. There
may be an argument for primary amputation in a
patient who is likely to mobilise well on a prosthesis
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and in whom the chances of a successful revasculari-
sation are slight.
More recently, available treatment options have
been extended by the possibility of pharmacotherapy
as a principal treatment. Published evidence so far
only relates to the use of pharmacotherapy in patients
with CLI who were unsuitable for any form of revas-
cularization or in whom attempts at revascularisation
have already failed. In these selected patients, phar-
macotherapy may help to avoid or delay a major
amputation and should be considered. The possibility
of pharmacotherapy as a primary alternative to revas-
cularization has not so far been studied. Its more
established role is as an adjunct to either endovascular
or surgical revascularization, where there is some evi-
dence that adjunctive pharmacotherapy improves
early and medium-term results at very little risk.
In summary, the management of a patient with CLI
should proceed rapidly in conjunction with delin-
eation of the arterial lesion. This is followed by a deci-
sion on the optimal form of revascularisation, which,
if successful, will reverse the changes of CLI with min-
imum risk. If both surgery and endovascular tech-
niques are equally feasible and likely to succeed ini-
tially and durably, the latter is preferred to surgery.
The second decision is whether to apply this form of
revascularisation or proceed to a primary amputation.
Pharmacotherapy is a useful adjunct, but its role as
primary treatment is not yet established.
04.2
Basic Treatment for Critical Limb Ischaemia
04.2.1
Control of Pain
A hallmark of CLI is ischaemic rest pain and painful
ulceration. Aetiology of the pain is multifactorial, but
it is primarily related to ischaemia of the skin in the
distal extremity. Pain control is a critical aspect of the
management of these patients. Ideally, relief of pain is
achieved by reperfusion of the extremity. However,
while setting up reperfusion, adequate pain control
must be a goal of management in all patients.
Furthermore, in patients for whom revascularisation
is not possible, acetaminophen, nonsteroidal anti-
inflammatory drugs, or narcotics may be necessary.
Pain control should be individualised and multifactorial.
Physicians should assess pain severity and adequa-
cy of pain relief in all patients at regular visits. Several
pain scales are available, but simple scales that range
from 0 to 10, with "0" indicating no pain and "lO"indi-
eating the most severe pain, are useful. Such scales
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should be evaluated and recorded in the chart at each
visit. Initial attempts at pain relief should include the
use of acetaminophen or nonsteroidal antiinflamma-
tory drugs. Caution should be used in the latter in
patients with hypertension or renal insufficiency.
Patients with severe unrelenting ischaemic pain also
may require narcotics for adequate pain relief. Control
of pain is usually more effective if analgesia is given
regularly rather than on demand. In patients undergo-
ing intervention, narcotics also may be required dur-
ing the postoperative period. Placing the affected limb
in the dependent position provides partial relief of
ischaemic pain in some patients. Tilting the bed or use
of a reclining chair therefore may be helpful measures
in addition to analgesia.
Spinal cord stimulation has also been used in
patients with inoperable severe lower extremity
ischaemia (see also D 4.16.4, P S223). However, it cur-
rently cannot be recommended in patients with CLI.
See Recommendation 82 (below). Epidural block is
another effective form of pain control in various ABPI
cases.
Recommendation 82: Pain control in critical limb
ischaemia
Adequate treatment of ischaemic pain is mandatory
in all patients with critical limb ischaemia and may
require short-term use of narcotics. Pain control
should be individualised and multifactorial.
However, pain control treatment should not delay
definitive treatment of the arterial lesion.
D4.2.2
Foot Care in Patients With Critical Limb Ischaemia
Patients with chronic CLI must pay particular atten-
tion to proper foot care and avoid trauma to their
extremities. These patients should be evaluated by a
podiatrist and evaluated for proper foot care.
Extremes of heat and cold should be avoided. Even
mild physical trauma can convert a patient from hav-
ing intact skin to an ischaemic ulcer. Thus, local meas-
ures are extremely important in the overall manage-
ment of these patients (see also D 1.4, The Diabetic
Foot, p S148).
D 4.2.3
Treatment of Life-Threatening Coexisting Disease
Patients with CLI are at the highest risk for subse-
quent myocardial infarction, stroke, and vascular
death. Therefore, in addition to addressing the needs
of their extremity, it is critical to reduce the systemic
risk of mortality in this patient population. Many of
these patients have impaired cardiac and renal func-
tion, sometimes having frank cardiac or renal failure.
These coexisting conditions require active treatment
by an expert in these areas. Improvement of cardiac
output also will inevitably improve peripheral perfu-
sion and go some way toward treating the CLI.
D4.2.4
Treatment of Ulcers and Gangrene
Topical therapy
Several attempts have been made to improve topical
therapy for ischaemic wounds in patients with CLI.
This includes the use of topical antibiotics, growth fac-
tors, and debriding agents. These treatments are
attractive and are often highly promoted by their
sponsors. However, there are almost no controlled
randomised trials to document the benefits of any top-
ical agent to augment wound healing in this patient
population. There may be substantial risk to the use of
this therapy, because allergic reactions leading to der-
matitis can be common with topical antibiotics.!
Furthermore, reliance on topical therapy carries the
risk of delaying reperfusion, and, except in neuro-
pathic ulcers, topical agents are unlikely to be success-
ful as the sole therapy. These agents are also expensive
and often unnecessarily raise the expectation of the
patient for a good result despite the absence of thera-
peutic efficacy.
Several novel dressings also have been proposed
to treat these patients. These include hydrophilic
dressings and seaweed. Most of the experience with
these dressings has been in venous ulcers and not
arterial ischaemic ulcers. Again, there are no data to
support their use. Local treatment should aim to
save as much skin tissue as possible; debridement
should be avoided or kept at a minimum. Wet dress-
ings, soaked in saline, can be used a few times a day
to eliminate pus and tissue debris. Moist dressings
also may be useful in reducing pain. Only once the
ulcer has dried out should dry dressings be used.
There is no indication for immobilising a patient
with an ischaemic ulcer, unless the ulcer is on a
weight-bearing area. A review of a few studies with
becaplermin (rhPDGF-BB) gel suggests that ulcer
healing may be improved.? The effectiveness of cur-
rent topical agents-antibiotics, growth factors or
hormones, debriding agents, or occlusive dress-
ings-is not established.
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Recommendation 83: Topical therapy for ischaemic
ulceration
Topical therapy for ischaernic ulceration should be
guided by the principles of wound care. The
extremities should be kept clean, with appropriate
debridement.
Systemic therapy
The use of systemic antibiotics may be indicated in
patients with cellulitis. This is commonly seen in
patients with diabetes with ischaernic wounds and
may occur in any patient who converts from dry to
wet gangrene, or who develops an infected ulcer.
Signs and symptoms include swelling, redness, and
tenderness at the site of infection. Bacteriology of
these wounds is often polymicrobial, particularly in
patients with diabetes. Therefore, signs of infection
need to be aggressively treated . This often requires the
use of 'systemic antibiotics to achieve adequate blood
levels. Additional systemic agents for treating
ischaemic wounds have not undergone rigorous trials.
Anticoagulation is generally not warranted except in
an attempt to maintain graft patency (see D 4.3.3,
Pharmacotherapy Other Than Prostanoids, p 5169,
and D 4.13.3, Other Drugs, p 5210). Antiplatelet thera-
py is useful asalready described to reduce the sys-
temic risk of cardiovascular disease (see
Recommendation 28, p 5871.
Recommendation 84: Systemic antibiotic therapy in
patients with critical limb ischaemia
Systemic antibiotics are required in patients who
develop cellulitis or spreading infection in
ischaernic ulcers or gangrene but should not delay
more definitive treatment.
D 4.2.5
Control of Risk Factors
Patients with CLI have the same cardiovascular risk
factor profile as patients with claudication. However,
patients with CLI have a more diffuse and extensive
degree of atherosclerosis. Therefore, their risk of car-
diovascular events and mortality is higher than that of
patients with claudication. Despite the end-stage
nature of this disease, aggressive systemic risk factor
modification is still warranted.
Smokillg cessation
The progression of peripheral arterial disease from
asymptomatic to claudication to ischaemic rest pain is
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highly associated with cigarette smoking. In patients
with severe disease, graft patencies are clearly
improved by smoking cessation. This is true for both
vein as well as prosthetic graft material. Amputation
rates are also highly correlated with persistent ciga-
rette smoking. In two series, the amputation rate was
between 11% and 23% in those who continued to
smoke, versus 0 to 10% in those who were smoking
abstinent.3 Finally, patient survival at 1/ 3, and 5 years
is also highly correlated with smoking. Therefore, in
patients with severe end-stage di sease, smoking cessa-
tion is still highly beneficial (see Recommendation 22,
p 569).
Hypertellsioll
Hypertension is a risk factor for all forms of cardio-
vascular disease. Although blood pressure elevations
are a risk factor for peripheral arterial disease, main-
taining an adequate blood pressure is important for
limb perfusion. In patients with claudication, aggres-
sive treatment of hypertension is associated with a
modest reduction in treadmill exercise performance.
In patients with severe chronic limb ischaemia,
aggressive blood pressure treatment may decrease
limb perfusion and thus result in worsening ischaemic
rest pain or delayed healing of ischaemic ulcers.
Historically, patients with CLI have been treated by
plasma volume expansion to increase blood pressure,
thereby improving distal blood flow,' This therapy
may be associated with temporary benefit but does
expose the patient to the risk of stroke, congestive
heart failure, and other untoward cardiovascular
events. Therefore, inducing hypertension in this
patient population is not recommended. Conversely,
patients hospitalised for treatment of their severe leg
ischaemia should not have their blood pressure acute-
ly lowered unless there is evidence of active coronary
ischaemia or congestive heart failure. Because there is
the possibility of vasoconstriction with beta-blocker
antihypertensive agents, their use in CLI should be
carefully considered. When such antihypertensives
are used, CLI patients should be monitored for wors-
ening of ischaemic ulcers.
Diabetes
Diabetes is an important risk factor for all forms of
peripheral arterial disease and also greatly contributes
to CLI (sec A 2/ Epidemiology, Natural History, Risk
Factors, p 54). In addition to the risk of atherosclerotic
arterial occlusive disease, patients with diabetes also
develop neuropathy, which increases the risk for
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developing nonhealing neurotrophic ulcers. In addi-
tion to the neuropathy, hyperglycaemia will inhibit
white cell function, thus predisposing the patient to
infection (see also D 1.4, Diabetic Foot p 5148). A
comprehensive approach to treating patients with dia-
betes would include proper footwear, with attention
to areas of trauma from poorly fitting shoes (see D
4.2.2, Foot Care, p 5165). Patients with nonheaIing
ulcers often need to be treated in the hospital to pro-
vide comprehensive management, including wound
care and eventually systemic antibiotics. In addition,
aggressive control of blood sugar is warranted in these
patients, with an attempt to maintain fasting blood
sugars below 120 mg/dL and postprandial sugars less
than 180 mg/dL. Chronic management should
attempt to normalise glycohaernoglobin levels to less
than 7.0% (see Recommendation 23, p 569).
Hypcrlipidnclllin
The lipid risk profile for patients with peripheral arte-
rial disease is similar between those with claudication
and those with CLI. There arc no data regarding rec-
ommendations in the severe leg ischaemia patient
population. However, extrapolation from patients
with intermittent claudication as well as from the
National Cholesterol Education Program Guidelines
would recommend aggressive treatment of LDL cho-
lesterol levels and attempts to raise the HDL choles-
terol and lower triglyceride levels . Therefore, patients
with CLI should have an LDL cholesterol level main-
tained at 100 mg/dL or less (sec Recommendation 25,
p 570). The goals of therapy are to reduce the systemic
risk of myocardial infarction and cardiovascular
death, as well as to delay the progression of peripher-
al atherosclerosis.
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o 4.3
Pharmacotherapy for Critical limb Ischaemia
04.3.1
Introduction
For decades, pharmaceutical and clinical research aimed
at improving the morbidity of claudication has centred
around vasodilators. Direct-acting vasodilators can
increase blood flow in normal resting skeletal muscle.
However, it is unlikely that any vasodilator can signifi-
cantly increase blood flow distal to a physical occlusion.
Autoregulatory mechanisms in skeletal muscle beds
produce dilation in response to ischaemia; hence,
vasodilators will increase blood flow primarily to non-
ischaemic areas. The concept of vasodilatation has
moved to vasoreactive or vasorecruiting drugs and
more recently to agents improving unbalanced or com-
promised microcirculation distal to an arterial obstruc-
tion. Another approach is to search for compounds that
improve the blood rheology. The use of "thrombolytic
drugs in CLI is also to be considered, most often to be
followed by endovascular or surgical treatment.
The ideal treatment for critical limb ischaemia must be
the elimination or bypass of the occlusions in the larger
arteries, but this is often impossible or else it fails. An
alternative in these cases is to try to modify the conse-
quences of the low perfusion pressure on the distal
microcirculation sufficiently by' some form of pharma-
cotherapy to reverse the rest pain and avoid amputation.
Pharmacological management of CLI must be based
on an improved understanding of its pathophysiology.
The main components, lack of autoregulation of the
microvascular flow-regulating system and inappropri-
ate activation of the microvascular defence system, are
both thought to be significantly regulated by prostacy-
clin.' Breakdown of the microvascular flow-regulating
system is manifested in particular by abnormal vaso-
motion and a maldistribution of blood flow away from
the nutritive skin capillaries. Activation of the microvas-
cular defence system results in interacting activation of
white blood cells, platelets, and the damaged endotheli-
um . The resultant capillary obstruction, increased capil-
lary permeability, tissue oedema, and the liberation of
activated products of leukocytes, such as oxygen free
radicals, platelet-activating factor, and proteolytic
enzymes, leads to a vicious cycle with further capillary
obstruction.
o 4.3.2
Prostanolds
Prostanoids have been shown to have beneficial
effects on most of the microcirculatory components by
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